ReichK, ThyssenJP, BlauveltA, et al.Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet, 2022; 400: 273–282.
2.
BieberT, SimpsonEL, SilverbergJI, et al.Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med, 2021; 384: 1101–1112.
3.
SimpsonEL, SinclairR, FormanS, et al.Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet, 2020; 396: 255–266.
4.
KingB, OhyamaM, KwonO, et al.Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med, 2022; 386: 1687–1699.
5.
SimpsonEL, PappKA, BlauveltA, et al.Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol, 2022; 158: 404–413.
